CD274 and melanoma: LDH has also been evaluated as a biomarker for melanoma patients receiving anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapy, where elevated baseline LDH levels are associated with reduced OS (HR = 2.44; 95% CI, 1.95–3.04; p < 0.001) and shorter PFS (HR = 1.61; 95% CI, 1.34–1.92; p < 0.001) [25].